Characteristics of each of the seven Crohn’s disease control patients who never received Infliximab, who developed neoplasia during follow up
| Pt No | Sex | CD site | CD type | CD duration (y) | Type of neoplasia | Age at diagnosis of neoplasia (outcome) | ISS (months) | Time since ISS |
|---|---|---|---|---|---|---|---|---|
| ISS, immunosuppressants; F, female; M, male; I, ileum; C, colon; I-C, ileum-colon; L, luminal; F, fistulising; AZA, azathioprine; ND, not done. | ||||||||
| 1 | M | I-C | L | 27 | Adenocarcinoma caecum | 61 Remission | ND | ND |
| 2 | F | C | L | 1 | Adenocarcinoma caecum | 27 Remission | ND | ND |
| 3 | F | I-C | F | 7 | Adenocarcinoma rectum | 45 Remission | ND | ND |
| 4 | M | I | F | 22 | Spinalioma | 33 Remission | AZA (46) | 46 |
| 5 | F | I-C | L | 12 | Basalioma | 58 Remission | AZA (24) | 24 |
| 6 | F | I-C | F | 13 | Breast cancer | 72 Remission | ND | ND |
| 7 | F | I-C | F | 12 | Non-Hodgkin’s lymphoma | 36 Remission | AZA (48) | 120 |